Health Catalyst, Inc. (NASDAQ:HCAT) Receives $4.32 Consensus PT from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been given a consensus recommendation of “Hold” by the fourteen ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $4.3182.

Several research firms recently commented on HCAT. William Blair reiterated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. UBS Group restated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating on the stock in a report on Tuesday, November 11th. Citigroup dropped their price objective on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating for the company in a research note on Friday, January 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th.

Health Catalyst Stock Up 1.8%

HCAT opened at $1.73 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. The company has a market cap of $122.36 million, a price-to-earnings ratio of -1.09 and a beta of 1.73. Health Catalyst has a one year low of $1.67 and a one year high of $5.09. The business’s fifty day moving average is $2.21 and its two-hundred day moving average is $2.67.

Insiders Place Their Bets

In other news, Director Julie Larson-Green sold 47,997 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the transaction, the director directly owned 73,573 shares of the company’s stock, valued at $196,439.91. The trade was a 39.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Benjamin Landry sold 27,425 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $2.64, for a total value of $72,402.00. Following the sale, the general counsel directly owned 100,000 shares in the company, valued at approximately $264,000. The trade was a 21.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 17.2% during the second quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after buying an additional 1,793,374 shares during the period. Millennium Management LLC grew its stake in Health Catalyst by 2,513.3% in the 3rd quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock worth $4,530,000 after acquiring an additional 1,528,710 shares during the period. RA Capital Management L.P. acquired a new position in Health Catalyst in the 4th quarter valued at $1,897,000. HighMark Wealth Management LLC raised its holdings in Health Catalyst by 139.0% in the 4th quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company’s stock valued at $1,772,000 after acquiring an additional 431,200 shares during the last quarter. Finally, Nepsis Inc. lifted its stake in shares of Health Catalyst by 26.6% during the 4th quarter. Nepsis Inc. now owns 1,915,794 shares of the company’s stock worth $4,579,000 after purchasing an additional 402,762 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.